| Overview |
| bs-10470R-PE |
| DYNC1I1 Polyclonal Antibody, PE Conjugated |
| WB, FCM |
| Human, Rat |
| Mouse, Cow, Sheep, Pig, Horse, Chicken, Rabbit |
| Specifications |
| PE |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DYNC1I1 |
| 1-100/645 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1780 |
| O14576 |
| Cytoplasm |
| dynein, cytoplasmic, intermediate polypeptide 1; cytoplasmic dynein 1 intermediate chain 1; DH IC-1; dynein intermediate chain 1, cytosolic; cytoplasmic dynein intermediate chain 1; DC1I1_HUMAN; DYNC1I1; DNCI1; DNCIC1; Dynein cytoplasmic intermediate polypeptide 1. |
| This gene is a member of the Tyr protein kinase family and the epidermal growth factor receptor subfamily. It encodes a single-pass type I membrane protein with multiple cysteine rich domains, a transmembrane domain, a tyrosine kinase domain, a phosphotidylinositol-3 kinase binding site and a PDZ domain binding motif. The protein binds to and is activated by neuregulins and other factors and induces a variety of cellular responses including mitogenesis and differentiation. Multiple proteolytic events allow for the release of a cytoplasmic fragment and an extracellular fragment. Mutations in this gene have been associated with cancer. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized. [provided by RefSeq, Jul 2008]. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
Powered by Bioz